Recursion Pharmaceuticals
clinical phase sad mad trial initiated in trial design randomized double blind trial population healthy subjects sad mad primary objectives assess the safety tolerability of sad and mad of evaluate the profile of after single and multiple doses trial update enrollment is progressing in several sad cohorts and at least one cohort has been extremely safe and well tolerated complete safety and data expected study underway | Recursion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
126 of 143
Related slides by other companies
Aeglea BioTherapeutics
Investor Presentation
May 2023
phase clinical trial design | Aeglea BioTherapeutics
Allarity Therapeutics
Investor Conference
September 2022
platform extensively studied in clinical trials | Allarity Therapeutics
MAIA Biotechnology
Investor Presentation
October 2023
thio trial planned to expand best combination arms | MAIA Biotechnology
Graphite Bio
IPO
June 2021
phase cedar clinical trial design | Graphite Bio
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights